Pro-Dex (NASDAQ:PDEX) Announces Quarterly Earnings Results, Beats Estimates By $0.23 EPS

Pro-Dex (NASDAQ:PDEX) released its quarterly earnings data on Thursday. The medical instruments supplier reported $0.61 EPS for the quarter, topping the consensus estimate of $0.38 by $0.23, Zacks reports. Pro-Dex had a return on equity of 16.74% and a net margin of 9.17%.

Pro-Dex Stock Down 11.6 %

Pro-Dex stock opened at $37.97 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The stock has a market capitalization of $123.78 million, a PE ratio of 24.66 and a beta of 0.56. The business has a 50 day simple moving average of $47.43 and a 200-day simple moving average of $34.53. Pro-Dex has a 12 month low of $16.18 and a 12 month high of $59.60.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on PDEX shares. Ascendiant Capital Markets boosted their target price on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, November 11th. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th.

Insider Activity

In related news, Director Raymond E. Cabillot sold 1,200 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $47.76, for a total transaction of $57,312.00. Following the completion of the transaction, the director now owns 359,646 shares in the company, valued at $17,176,692.96. This represents a 0.33 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alisha Charlton sold 1,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $40.02, for a total transaction of $40,020.00. Following the completion of the transaction, the chief financial officer now directly owns 15,339 shares in the company, valued at $613,866.78. This represents a 6.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,670 shares of company stock worth $1,229,821 in the last quarter. Corporate insiders own 47.50% of the company’s stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.